Current practice in intermediate risk differentiated thyroid cancer – a review

被引：0
作者：
Rosalia do Prado Padovani
Fernanda Barbosa Duarte
Camila Nascimento
机构：
[1] Faculdade de Ciências Médicas da Santa Casa de São Paulo,Section of Endocrinology and Metabolism, Department of Medicine
[2] Rua Doutor Cesário Mota Junior,Nuclear Medicine Department
[3] ,undefined
[4] Institut Universitaire du Cancer de Toulouse-Oncopole,undefined
来源：
Reviews in Endocrine and Metabolic Disorders | 2024年 / 25卷
关键词：
Thyroid neoplasms; Thyroid cancer; Differentiated thyroid cancer; Radioactive iodine therapy; Iodine radioisotopes; Neoplasm recurrence; Therapy; Treatment outcome; Intermediate-risk papillary thyroid cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Although the overall prognosis for differentiated thyroid cancer (DTC) is excellent, a subset of patients will experience disease recurrence or may not respond to standard treatments. In recent years, DTC management has become more personalized in order to enhance treatment efficacy and avoid unnecessary interventions.
引用
收藏
页码：95 / 108
页数：13
相关论文
共 280 条
[1]  
Haugen BR(2016)2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Thyroid 26 1-133
[2]  
Alexander EK(2003)Thyroid carcinoma The Lancet 361 501-511
[3]  
Bible KC(2013)Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus Arq Bras Endocrinol Metabol 57 240-264
[4]  
Sherma SI(2010)Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System Thyroid 20 1341-1349
[5]  
Rosário PW(2016)Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study Clin Endocrinol (Oxf) 84 408-416
[6]  
Ward LS(2013)Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making Oral Oncol 49 676-683
[7]  
Carvalho GA(2015)Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer J Clin Endocrinol Metab 100 1529-1536
[8]  
Tuttle RM(2016)Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma Endocr Relat Cancer 23 367-376
[9]  
Tala H(2017)Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine Eur Thyroid J 6 65-74
[10]  
Shah J(2019)Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis Oral Oncol 90 17-22
12345678910